Got drug controller nod for Favipiravir's clinical trial on COVID-19 patients: CSIR DG

Shekhar Mande also said the Indian Institute of Chemical Technology (IICT), Hyderabad has developed the technology to make the drug Favipiravir.

Published: 09th May 2020 09:24 AM  |   Last Updated: 09th May 2020 09:24 AM   |  A+A-

Chennai people who are tested positive for coronavirus has been taken to hospital at Kannappar Thidal Periyamet in Chennai on Friday. (Photo | R Sathish Babu/EPS)


NEW DELHI: The Drug Controller of India has allowed a clinical trial of Favipiravir medicine, developed indigenously a CSIR laboratory, on coronavirus patients, Director-General Shekhar Mande said on Friday.

He said the Indian Institute of Chemical Technology (IICT), Hyderabad has developed the technology to make the drug Favipiravir.

The technology has been transferred to a private company, IICT Director S Chandrashekar said.

The company will now tie-up with hospitals for clinical trials so that the drug could be tested on patients suffering from COVID-19.

Approval from patients will be necessary as per the protocols, he said.

Mande said Favipiravir is used in countries such as China and Japan to treat influenza.

Whenever a virus enters a cell, it tries to create multiple replicas.

Favipiravir stops the replication process, he explained.

The CSIR has already tied up with Cadila Pharmaceuticals Ltd to evaluate Mycobacterium W (Mw) for faster recovery of hospitalised COVID-19 patients and minimise the spread of disease.

Mycobacterium W can reduce mortality of patients suffering from Gram-negative sepsis by 50 per cent.

Permission has been granted by the Drug Controller of India to conduct tests on critically ill COVD-19 patients at three major hospitals in the country, he said.

Mande said Mycobacterium W helps in boosting TH1 and TH2 cells, which in turn, builds immunity in fighting viruses and in this specific case the novel coronavirus.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp